Predictive Clinical-Biological Markers Over the First 3 Years of Nusinersen Treatment in SMA Type 1 Patients
Werdnig-Hoffmann disease, or type 1 Spinal Muscular Atrophy (SMA), is caused by insufficient SMN protein synthesis due to a genetic defect. Symptoms appear within the first 6 months of life, and without ventilatory support, life expectancy averages 2 years. This study aimed to monitor pNF-H neurofil...
Saved in:
| Main Authors: | Mihaela Badina, Andrada Mirea, Corina Sporea, Gabriel Cristian Bejan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Romanian Association of Balneology, Editura Balneara
2025-12-01
|
| Series: | Balneo and PRM Research Journal |
| Subjects: | |
| Online Access: | http://bioclima.ro/Balneo754.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evolution of Functional and Paraclinical Markers as Predictive Factors in Pediatric Late-Onset SMA Under Nusinersen Treatment: The Role of CSF pNF-H
by: Mihaela Badina, et al.
Published: (2025-12-01) -
Biomarker Evolution in Pediatric SMA: Insights from CSF pNF-H Dynamics and SMN2 Copy Number During Nusinersen Therapy
by: Mihaela Badina, et al.
Published: (2025-03-01) -
Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
by: Yiğithan Güzin, et al.
Published: (2024-11-01) -
The efficacy and safety of nusinersen within the expanded access program in Russia
by: S. B. Artemieva, et al.
Published: (2020-12-01) -
Molecular markers of disease severity and response to nusinersen therapy in 5q spinal muscular atrophy (literature review)
by: K. D. Popov, et al.
Published: (2023-10-01)